News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-01-16 pm EST			5-day change	1st Jan Change
55.26 ^USD	-2.40%		-1.07%	+2.45%

Jan. 13	Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $60 From $54, Maintains Outperform Rating	MT
Jan. 12	Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy	CI

Jan. 13	Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $60 From $54, Maintains Outperform Rating	MT
Jan. 12	Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy	CI
Jan. 12	Bristol-Myers Squibb Company Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 07:30 AM
Jan. 12	Bristol-Myers Squibb Says Phase 3 Trial of Camzyos Meets Primary Endpoint	MT
Jan. 12	Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)	BU
Jan. 12	BioXcel Therapeutics, Inc. Appoints Mark Pavao as Acting Chief Commercial Officer and Will Lead the Development and Execution of the Company's Commercial Plans	CI
Jan. 11	Precede Biosciences, Inc. announced that it has received $83.5 million in funding from 5AM Venture Management, LLC, Bristol-Myers Squibb Company, Oup Management Co., LLC, Binney Street Capital Fund, LLC, Labcorp Venture Fund	CI
Jan. 09	Scotiabank Adjusts Price Target on Bristol-Myers Squibb to $60 From $53, Maintains Sector Perform Rating	MT
Jan. 07	Mediar Therapeutics, Inc. announced that it has received $76 million in funding from a group of investors	CI
Jan. 07	UBS Upgrades Bristol-Myers Squibb to Buy From Neutral, Lifts Price Target to $65 From $46	MT
Jan. 06	Bristol Myers Squibb : Preliminary Q4 2025 Acquired IPRD & Licensing Income	PU
Jan. 06	Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million	DJ
Jan. 06	Alumis shares surge to record high as skin disease drug aces late-stage trials	RE
Jan. 05	Zenas BioPharma's immune disorder drug meets main goal in late-stage trial	RE
Jan. 05	Incyte's blood cancer therapy slows disease progression in trial	RE
Jan. 04	Amgen Inc. acquired Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company and Evotec SE in a transaction valued at $840 million.	CI
Jan. 02	Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference	BU
Jan. 01	Ex-dividend day	FA
Dec. 28	Louis Gerstner, former IBM CEO who revitalized 'Big Blue,' dies at 83	RE
Dec. 22	AstraZeneca's ceralasertib-Imfinzi drug combo misses survival target in lung cancer trial	RE
Dec. 19	US FDA approves Cytokinetics' heart disease drug	RE
Dec. 19	Sector Update: Health Care Stocks Rise Late Afternoon	MT
Dec. 19	Sector Update: Health Care	MT
Dec. 19	Bristol Myers Squibb announces deal with U.S. government	RE
Dec. 19	Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Technical Analysis: Bristol-Myers Squibb hesitates at a critical juncture

August 28, 2025 at 03:51 am EDT